Skip to main content
Premium Trial:

Request an Annual Quote

Cepheid Shares Spike on Analyst Upgrade

NEW YORK (GenomeWeb News) – Shares in Cepheid have climbed more than 8 percent today following a morning upgrade of the company's stock by an analyst with William Blair & Co.

Analyst Brian Weinstein upgraded Cepheid shares to "outperform" from "market perform," noting expected revenues from new diagnostic products and increased hospital spending in 2010.

In afternoon trading on Nasdaq, Cepheid's shares had risen 8.3 percent to $15.58 from $14.38 at close of market on Friday.

Last week, Sunnyvale, Calif.-based Cepheid said that the US Food and Drug Administration had granted Emergency Use Authorization for its Xpert Flu A Panel test; as well as permission to market its Xpert vanA test for the antimicrobial resistance gene most commonly associated with vancomycin-resistant enterococci.

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.